Matching Placebo BID

DRUG2 trials

Sponsors

Eisai Inc., Kanion & Huawe Medicine Co.,Ltd

Conditions

Obesity

Phase 3

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

CompletedNCT00395135

Eisai Inc.Obesity

Start: 2006-11-30End: 2009-02-28Updated: 2019-10-02

Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients

TerminatedNCT03720574

Kanion & Huawe Medicine Co.,LtdObesity

Start: 2019-09-17End: 2020-12-12Updated: 2022-05-02

Related Papers

Lorcaserin and metabolic disease: weight‐loss dependent and independent effects

Obesity Science & Practice2018-08-076 citations

Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with ≥5% weight loss

Postgraduate Medicine2016-09-232 citations

Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.

2016-05-178 citations

Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia

Postgraduate Medicine2016-04-2720 citations

Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials.

2013-05-0946 citations

Multicenter, placebo-controlled trial of lorcaserin for weight management.

2010-07-01603 citations